Lilly's dulaglutide: a blockbuster in the making
This article was originally published in Scrip
Executive Summary
The safety and efficacy profile of Lilly's dulaglutide must measure up to Novo Nordisk's Victoza if it is to become a contender in the diabetes market, but as Datamonitor Healthcare analyst Dr Sebastian Heinzmann explains, it could do more than just that.